Article info

Download PDFPDF

Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment

Authors

  1. Correspondence to Stuart A McIntosh; s.mcintosh{at}qub.ac.uk
View Full Text

Citation

Campbell AM, Morris M, Gallagher R, et al
Chemoprevention in BRCA1 mutation carriers (CIBRAC): protocol for an open allocation crossover feasibility trial assessing mechanisms of chemoprevention with goserelin and anastrozole versus tamoxifen and acceptability of treatment

Publication history

  • Received March 22, 2018
  • Revised September 24, 2018
  • Accepted November 2, 2018
  • First published December 22, 2018.
Online issue publication 
December 22, 2018

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.